1008 Beach Avenue
Vancouver, BC V6E 1T7
Full Time Employees:
|Mr. Jeffrey A. Bacha B.Sc., M.B.A.||Exec. Chairman||N/A||N/A||1968|
|Dr. Mads Daugaard||Pres & Chief Scientific Officer||N/A||N/A||N/A|
|Mr. David Hyman CA, CBV||CFO & Corp. Sec.||N/A||N/A||1973|
|Dr. John Langlands Ph.D.||Chief Operating Officer||N/A||N/A||N/A|
Rakovina Therapeutics Inc., a biopharmaceutical company, focuses on development of cancer therapies based on novel DNA-damage response technologies. The company's lead pipeline products include kt-2000, the next generation oral targeted small molecule PARP inhibitors; kt-3000, a class of small-molecule drug candidates to overcome and prevent resistance to treatment with first generation DDRi; and kt-4000 to cause targeted DNA-damage to a tumor cell's DNA while simultaneously inhibiting the tumor's DNA damage response. Rakovina Therapeutics was founded in 2020 and is headquartered in Vancouver, Canada.
Rakovina Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.